[
  {
    "ts": null,
    "headline": "Biogen Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Biogen Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=ae1098681b70c19abb87611b1c197b27f76c98db9faf08f427562ff25d0b9c4d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732036020,
      "headline": "Biogen Inc. stock underperforms Tuesday when compared to competitors",
      "id": 131611821,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=ae1098681b70c19abb87611b1c197b27f76c98db9faf08f427562ff25d0b9c4d"
    }
  },
  {
    "ts": null,
    "headline": "Biogen : to Participate in the 7th Annual Evercore HealthCONx Conference",
    "summary": "Cambridge, MA, - - Biogen Inc. announced today that Alisha Alaimo, President, Head of North America, will participate in a fireside chat during the 7th Annual Evercore HealthCONx Conference. The...",
    "url": "https://finnhub.io/api/news?id=92581c6dc2ebd096a4d0b2d8877b4cc1d269de9af9edf771b3ee9eb2e5f73a36",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732035967,
      "headline": "Biogen : to Participate in the 7th Annual Evercore HealthCONx Conference",
      "id": 131492640,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Cambridge, MA, - - Biogen Inc. announced today that Alisha Alaimo, President, Head of North America, will participate in a fireside chat during the 7th Annual Evercore HealthCONx Conference. The...",
      "url": "https://finnhub.io/api/news?id=92581c6dc2ebd096a4d0b2d8877b4cc1d269de9af9edf771b3ee9eb2e5f73a36"
    }
  },
  {
    "ts": null,
    "headline": "Samsung Bioepis and Biogen Receive European Commission Approval for Aflibercept Biosimilar, OPUVIZ",
    "summary": "INCHEON, CAMBRIDGE - Samsung Bioepis Co., Ltd. and Biogen Inc. today announced that the European Commission has approved OPUVIZ 40 mg/mL solution for injection in a vial, a biosimilar referencing...",
    "url": "https://finnhub.io/api/news?id=2089d2dbcdf1ceafea9e0d0567baa1db07132a4273749b2a38d7a0d44f5bf9d2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732010111,
      "headline": "Samsung Bioepis and Biogen Receive European Commission Approval for Aflibercept Biosimilar, OPUVIZ",
      "id": 131471470,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "INCHEON, CAMBRIDGE - Samsung Bioepis Co., Ltd. and Biogen Inc. today announced that the European Commission has approved OPUVIZ 40 mg/mL solution for injection in a vial, a biosimilar referencing...",
      "url": "https://finnhub.io/api/news?id=2089d2dbcdf1ceafea9e0d0567baa1db07132a4273749b2a38d7a0d44f5bf9d2"
    }
  },
  {
    "ts": null,
    "headline": "Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity",
    "summary": "Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activityA greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care aloneSystemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ sy",
    "url": "https://finnhub.io/api/news?id=d834ea3b92155cc3d3ee0132551abd9fb02aad5463c9bbf063ff70ef8cdf61c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731996000,
      "headline": "Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity",
      "id": 131465273,
      "image": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activityA greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care aloneSystemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ sy",
      "url": "https://finnhub.io/api/news?id=d834ea3b92155cc3d3ee0132551abd9fb02aad5463c9bbf063ff70ef8cdf61c5"
    }
  },
  {
    "ts": null,
    "headline": "Biogen: positive phase 3 results in lupus",
    "summary": "UCB and Biogen announce that they have presented positive detailed results from the Phase 3 PHOENYCS GO study evaluating their dapirolizumab pegol in moderate-to-severe systemic lupus erythematosus...",
    "url": "https://finnhub.io/api/news?id=45a4ed140a3923715bcaa003220d6a4a17fb86e8acbacb0051513f51177c6656",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731985455,
      "headline": "Biogen: positive phase 3 results in lupus",
      "id": 131465712,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "UCB and Biogen announce that they have presented positive detailed results from the Phase 3 PHOENYCS GO study evaluating their dapirolizumab pegol in moderate-to-severe systemic lupus erythematosus...",
      "url": "https://finnhub.io/api/news?id=45a4ed140a3923715bcaa003220d6a4a17fb86e8acbacb0051513f51177c6656"
    }
  }
]